Insulin-like growth factor-binding protein 2 (IGFBP-2) emerges as an independent predictor of adverse left ventricular remodeling in heart attack survivors, with 34% of 155 first-time patients developing harmful heart chamber enlargement within 12 months. Higher baseline IGFBP-2 levels significantly correlated with increased risk, improving predictive accuracy from 73.5% to 80.1% when added to standard clinical models. This finding illuminates a crucial metabolic pathway linking growth factor regulation to heart failure development. IGFBP-2 normally modulates insulin-like growth factor activity, which influences cardiac muscle growth and repair. Elevated levels may signal dysregulated tissue remodeling processes that promote maladaptive rather than healing responses after heart damage. The protein's predictive power could revolutionize post-heart attack care by identifying high-risk patients who need aggressive preventive interventions before heart failure symptoms appear. However, this preprint awaits peer review, and the relatively modest sample size limits generalizability. The metabolic connection—linking diabetes-related markers to heart remodeling—suggests lifestyle interventions targeting insulin resistance might prevent progression. If validated, IGFBP-2 testing could become standard practice for personalizing cardiac rehabilitation and medication intensity after myocardial infarction.